OGEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OGEN (OGEN).
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription leading to cell proliferation and differentiation in target tissues.
| Metabolism | Hepatic metabolism via CYP3A4 to estrone, estriol, and conjugates; enterohepatic recirculation. |
| Excretion | Renal elimination of conjugated metabolites (estrone sulfate, estradiol glucuronide) accounts for >95% of excretion; fecal elimination is <5%. |
| Half-life | Terminal elimination half-life of estrone is approximately 10-24 hours (mean ~14 hours); clinical context: permits once-daily dosing. |
| Protein binding | Estrone is approximately 98% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Volume of distribution for estrone is approximately 12 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability of estrone from OGEN is approximately 5-10% due to extensive first-pass metabolism; bioavailability of conjugated estrogens (e.g., piperazine estrone sulfate) is higher, but specific to OGEN is ~5-10%. |
| Onset of Action | Oral: clinical effects (e.g., relief of vasomotor symptoms) typically onset within 2-4 weeks of continuous therapy. |
| Duration of Action | Duration of action for relief of menopausal symptoms is sustained with daily dosing; effects wane over 1-2 weeks after discontinuation. |
| Molecular Weight | 436.6 |
0.75 mg orally once daily, cyclically (3 weeks on, 1 week off) for moderate to severe vasomotor symptoms associated with menopause.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustment provided by manufacturer; use with caution in patients with severe renal impairment. |
| Liver impairment | Contraindicated in patients with known or suspected hepatic disease; no dose adjustment recommended due to contraindication. |
| Pediatric use | Not indicated for use in pediatric patients. |
| Geriatric use | Use lowest effective dose for shortest duration; no specific dose adjustment recommended, but monitor for estrogen-related adverse effects. |
| 1st trimester | Estropipate is contraindicated in pregnancy. Use during the first trimester may cause fetal harm based on known effects of estrogens on fetal development. |
| 2nd trimester | Contraindicated in pregnancy. Estrogens should not be used during the second trimester due to potential adverse effects on the fetus. |
| 3rd trimester | Contraindicated in pregnancy. Use during the third trimester is associated with an increased risk of congenital anomalies and other fetal complications. |
Clinical note
Comprehensive clinical and safety monograph for OGEN (OGEN).
| Placental transfer | Estropipate crosses the placenta. Estrogens are known to be transferred to the fetus, with potential for fetal effects. |
| Breastfeeding | Estrogens are excreted in human breast milk in small amounts. Use during breastfeeding is not recommended, as it may reduce milk production and quality. The long-term effects on the nursing infant are unknown. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction.
| Serious Effects |
PregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive deep vein thrombosis or pulmonary embolismActive arterial thromboembolic disease (e.g., stroke, myocardial infarction)Known hypersensitivity to estropipate or any of its ingredientsHepatic impairment or disease
| Precautions | Cardiovascular disorders (stroke, MI, DVT, PE), Malignant neoplasms (endometrial cancer, breast cancer), Gallbladder disease, Hypercalcemia, Visual abnormalities, Hepatic hemangiomas, Thyroid hormone metabolism alterations |
| Food/Dietary | Grapefruit juice may increase estropipate absorption and serum levels; avoid concurrent consumption. No other significant food interactions are documented. |
Loading safety data…
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | Estropipate is contraindicated in pregnancy. First trimester: associated with congenital anomalies (e.g., cardiovascular, genitourinary) based on observational studies; no adequate controlled studies. Second and third trimesters: continued exposure may increase risk of fetal genital anomalies, uterine growth restriction, and neonatal complications (e.g., jaundice, glucose intolerance). Use only if clearly needed during lactation; avoid in pregnancy. |
| Fetal Monitoring | Monitor maternal blood pressure, liver function, and glucose levels. Assess fetal growth via ultrasound if prolonged use. Observe neonates for jaundice and hypoglycemia if exposed. |
| Fertility Effects | Estropipate may inhibit ovulation; reversibility expected upon discontinuation. No long-term effect on fertility documented. |
| Clinical Pearls | Estropipate (OGEN) is a conjugated estrogen with a sulfate ester that improves water solubility and absorption. It is used for vasomotor symptoms of menopause and vulvovaginal atrophy. Due to its estrogenic activity, it increases the risk of endometrial hyperplasia; thus, in patients with an intact uterus, a progestin must be co-administered. Estrogen therapy may also increase the risk of venous thromboembolism and breast cancer. Use the lowest effective dose for the shortest duration. |
| Patient Advice | Take OGEN exactly as prescribed; do not change dose or stop without consulting your healthcare provider. · Report any unusual vaginal bleeding or spotting promptly, as it may indicate endometrial changes. · Be aware of increased risk of blood clots; seek immediate medical attention for sudden chest pain, shortness of breath, or leg swelling. · Avoid smoking, as it increases the risk of cardiovascular adverse effects. · Attend regular breast exams and mammograms as recommended. · If you have an intact uterus, you will likely need to take a progestin along with estrogen to protect the uterine lining. |